New COVID-19 Clinical Guidelines to help Australian clinicians deliver best care

A coalition of peak Australian experts have come together to develop new ‘living guidelines’ that will provide continuously-updated, evidence-based guidance to clinicians treating people with confirmed or suspected COVID-19 infections across primary, acute and critical care settings.

The guidelines will form a key part of Australia’s response to COVID-19. Clinicians are being encouraged to submit questions or suggestions.

The National COVID-19 Clinical Evidence Taskforce is convened by the Australian Living Evidence Consortium, based at Cochrane Australia at Monash University. The Taskforce received $1.5 million from the Medical Research Future Fund (MRFF) to deliver the guidelines.

The initial focus of the guidelines will be:
• definitions of disease severity
• monitoring and markers of clinical deterioration
• antiviral medications and other disease modifying treatments
• respiratory support